Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M

MARAVAI LIFESCIENCES HOLDINGS, INC.

2023-FY EPS reported -$0.90 revenue$288,945,000

Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.
Nucleic Acid Production revenue $58.8M in Q4, down 69% YoY; COVID CleanCap revenue fell $105M YoY.
Full year 2023 revenue $288.9M (down 67% YoY); net loss $138.4M vs net income $490.7M.
Introduced 2024 revenue guidance of $265M-$285M, below 2023 actual.
Announced CleanCap patent awards in China/Canada, supply deal with FUJIFILM Toyama Chemical, and Cygnus-Dyadic partnership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Fourth Quarter 2023 results: revenue Quarterly revenue of $74.1 million, net income Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets.

Period: Fourth Quarter 2023
Revenue: Quarterly revenue of $74.1 million
Net income: Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets
Result: reported results

Exact text from the filing

Quarterly revenue of $74.1 million, Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets, and Adjusted EBITDA margin of 28%;

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MARAVAI LIFESCIENCES HOLDINGS, INC. reported financial results for for the fourth quarter ended December 31, 2023.

Period: for the fourth quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the fourth quarter of 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2024 results: revenue $265.0 million to $285.0 million. Guidance initiated.

Period: Full Year 2024
Revenue: $265.0 million to $285.0 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Introduced full year 2024 revenue guidance range of $265.0 million to $285.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2023 results: revenue Annual revenue of $288.9 million, net income Net loss of $(138.4) million.

Period: Full Year 2023
Revenue: Annual revenue of $288.9 million
Net income: Net loss of $(138.4) million
Result: reported results

Exact text from the filing

Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%;

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-24-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.